Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Earlier today, the Institute for Clinical and Economic Review (ICER) shared its Final Evidence Report on Midomafetamine-Assisted Psychotherapy for Post-Traumatic Stress Disorder (PTSD).1 Lykos...
Dear Colleagues, As you know, Lykos is entering the final stages of a multi-year effort to study and apply for approval from the U.S. Food and Drug Administration (FDA) for midomafetamine (MDMA)...
Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the outcome of the U.S. Food and Drug Administration's ("FDA") Psychopharmacologic Drugs Advisory...
Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective...
Meeting to be held on June 4, 2024 First FDA Advisory Committee meeting for potential new PTSD treatment in 25 years SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Lykos Therapeutics (formerly MAPS...